March 2012. Volume 8. Number 1

Is a catch-up dose of 13-valent pneumococcal vaccine cost-effective?

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Boccalini S, Azzari C, Resti M, Valleriani C, Cortimiglia M, Tiscione E et al. Economic and clinical evaluation of a catch-up dose of 13-valent pneumococcal conjugate vaccine in children already immunized with three doses of the 7-valent vaccine in Italy. Vaccine.2011;28;29:9521-8.
Reviewers: Ochoa Sangrador C1, Andrés de Llano JM2.
1Servicio de Pediatría. Hospital Virgen de la Concha. Zamora. España.
2Servicio de Pediatría. Hospital General del Río Carrión. Palencia. España.
Correspondence: Carlos Ochoa Sangrador. Email: cochoas@meditex.es
Reception date: 23/01/2012
Acceptance date: 24/01/2012
Publication date: 26/01/2012

Abstract

Authors’ conclusion: to vaccinate children up to 24 months of life, previously immunized with 7-valent pneumococcal conjugate vaccine, in a catch-up programme, with a catch-up 13-valent vaccine is justified from an economic point of view. The average cost per event avoided is 1674 Euros vaccinating children up to 24 months, and increases to 2522 Euros by vaccinating up to 60 months of age. The cost per year of life saved for different vaccination strategies is always acceptable (from 12,250 Euros to 22,093 Euros).

Reviewers’ commentary: if the cost-effectiveness estimates were similar in our sanitary system, a catch-up campaign with a 13-valent vaccine would be an intervention to consider, although, given its high price, in competition with others of similar cost-utility. However, it is needed to know the impact of changes in some assumptions of effectiveness, of which there is no direct evidence, which could have biased the cost-utility estimates.

How to cite this article

Ochoa Sangrador C, Andrés de Llano JM. ¿Es coste-efectiva la vacunación de rescate frente a 13 serotipos de neumococo? Evid Pediatr. 2012;8:10.

AVC | Critically appraised articles

Boccalini S, Azzari C, Resti M, Valleriani C, Cortimiglia M, Tiscione E et al. Economic and clinical evaluation of a catch-up dose of 13-valent pneumococcal conjugate vaccine in children already immunized with three doses of the 7-valent vaccine in Italy. Vaccine.2011;28;29:9521-8.
Reviewers: Ochoa Sangrador C1, Andrés de Llano JM2.
1Servicio de Pediatría. Hospital Virgen de la Concha. Zamora. España.
2Servicio de Pediatría. Hospital General del Río Carrión. Palencia. España.
Correspondence: Carlos Ochoa Sangrador. Email: cochoas@meditex.es
Reception date: 23/01/2012
Acceptance date: 24/01/2012
Publication date: 26/01/2012

How to cite this article

Ochoa Sangrador C, Andrés de Llano JM. ¿Es coste-efectiva la vacunación de rescate frente a 13 serotipos de neumococo? Evid Pediatr. 2012;8:10.

References

  1. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19:187-95.
  2. Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J. 2002;21:810-5.
  3. Rubin JL, McGarry LJ, Strutton DR, Klugman KP, Pelton SI, Gilmore KE et al. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States.Vaccine. 2010;28:7634-43.
26/01/2012

Linked Comment